Fig. 3: Abundance of LOX/LOXL enzymes in human skin dermis and scar. | Nature Communications

Fig. 3: Abundance of LOX/LOXL enzymes in human skin dermis and scar.

From: Topical application of an irreversible small molecule inhibitor of lysyl oxidases ameliorates skin scarring and fibrosis

Fig. 3

qPCR of LOX family of enzymes from matched normal skin and scar fibroblasts (a). LOX and LOXL1 expression is significantly increased in scar fibroblasts (p = 0.0317 and p < 0.0001 respectively using Mann–whitney two-tailed test). b Immunohistochemistry showed increased LOX intensity in scar tissue samples when compared to normal skin (n = 11 matched biologically independent human samples of scar and skin). Images of skin (c) and normotrophic scar (d) immunohistochemistry for LOX from an individual patient (n = 11 independent biological pairs were imaged and this shows one matched pair of normal skin and scar from a single individual). Data are shown for each matched pair of normal skin and scar samples. Subsequent statistical analysis was performed using Wilcoxon matched-pairs signed rank test (p = 0.0068). Scale bars 300 microns. *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001. Source data are provided as a Source Data file.

Back to article page